Menu
Back to User profile » Dr Adnan A Kadi
Papers published by Dr Adnan A Kadi:
LC–MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation
Attwa MW, Abdelhameed AS, Kadi AA
Drug Design, Development and Therapy 2021, 15:3915-3925
Published Date: 15 September 2021
Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach
Abdelhameed AS, Attwa MW, Kadi AA
Drug Design, Development and Therapy 2020, 14:5259-5273
Published Date: 30 November 2020
LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay
Attwa MW, Abdelhameed AS, Al-Shakliah NS, Kadi AA
Drug Design, Development and Therapy 2020, 14:4439-4449
Published Date: 23 October 2020
Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
Attwa MW, Kadi AA, Abdelhameed AS, Alhazmi HA
Drug Design, Development and Therapy 2020, 14:783-793
Published Date: 25 February 2020
Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry
Attwa MW, Kadi AA, Darwish HW
Drug Design, Development and Therapy 2020, 14:111-119
Published Date: 10 January 2020
Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling
Abdel-Aziz HA, Eldehna WM, Keeton AB, Piazza GA, Kadi AA, Attwa MW, Abdelhameed AS, Attia MI
Drug Design, Development and Therapy 2017, 11:2333-2346
Published Date: 9 August 2017